Meeting
2016 Gastrointestinal Cancers Symposium
The prevalence RAS and BRAF mutations among patients in the Middle East and Northern Africa with metastatic colorectal cancer.
Authors
Tamer Garawin
Amgen, Thousand Oaks, CA
Tamer Garawin , Kimberly Lowe , George Kafatos , Samuel Murray
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 598)
DOI
10.1200/jco.2016.34.4_suppl.598
Abstract #
598
Poster Bd #
F3
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
First Author: Marc Peeters
Poster
2016 ASCO Annual Meeting
Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).
First Author: Tae Won Kim
Poster
2015 Gastrointestinal Cancers Symposium
Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC).
First Author: Cathy Eng
Poster
2014 Gastrointestinal Cancers Symposium
FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC).
First Author: Thomas Brodowicz